Published • loading... • Updated
FDA Seeks Public Feedback to Inform Regulatory Approach for Generative AI-Enabled Medical Devices
The agency is asking manufacturers, clinicians and the public to comment on risk assessment, premarket review and postmarket monitoring for GenAI devices.
- On Tuesday, the FDA published a discussion paper seeking public input on regulating generative AI-enabled medical devices, with feedback accepted under docket FDA-2026-N-7874 until October 19, 2026.
- Unlike traditional software, generative AI creates variable outputs and potential "hallucinations" that are harder to regulate, prompting the Center for Devices and Radiological Health to develop a new framework.
- The agency proposed a "competency-based approach" to premarket evaluation, inspired by how human clinicians are credentialed, involving benchmarking and clinical confirmation of device performance.
- To balance innovation and safety, the FDA is considering accepting "greater premarket uncertainty" while increasing reliance on postmarket monitoring to track device performance in the real world.
- Acting FDA Commissioner Kyle Diamantas stated the announcement reflects a commitment to leveraging AI to improve patient health outcomes, aligning with Trump Administration priorities to accelerate innovative medical products.
Insights by Ground AI
11 Articles
11 Articles
FDA considering doctor-like assessment for AI-enabled devices
·Arlington, United States
Read Full Article
Coverage Details
Total News Sources11
Leaning Left2Leaning Right1Center5Last UpdatedBias Distribution63% Center
Bias Distribution
- 63% of the sources are Center
63% Center
L 25%
C 63%
12%
Factuality
To view factuality data please Upgrade to Premium
